TG Therapeutics, Inc. (TGTX) 股票分析

公司概述

TG Therapeutics, Inc. operates as a commercial-stage biopharmaceutical enterprise dedicated to the acquisition, development, and commercialization of novel therapeutic interventions for B-cell mediated diseases across the United States and international markets. The company functions within the Healthcare sector, specifically the Biotechnology industry, a classification that denotes its focus on drug discovery and patient care rather than manufacturing or consumer services. As of the latest data, the enterprise maintains a market capitalization of $5.46 billion, generates annual revenue of $616.29 million, and employs a workforce of 399 individuals. These valuation and revenue metrics position the company as a mid-to-large-cap entity within the specialized biotechnology landscape, indicating a significant operational footprint relative to smaller clinical-stage peers while reflecting the capital-intensive nature of biopharmaceutical development.

财务健康

The company reported revenue of $616.29 million and net income of $447.18 million over the trailing twelve months, with EBITDA reaching $123.38 million; the substantial gap between revenue and net income reveals a highly efficient cost structure where operating expenses are covered with high profitability. However, the free cash flow stands at $-43,978,876, which indicates that despite accounting profits, the company is currently burning cash, likely due to heavy capital expenditures on research, clinical trials, or working capital requirements typical of biotech firms. Profitability is underscored by three distinct margins: a gross margin of 83.7%, an operating margin of 26.2%, and a profit margin of 72.6%, all of which suggest strong pricing power and cost control at the production and operational levels. Regarding leverage, the firm holds $141.97 million in cash against $254.40 million in debt, resulting in a debt-to-equity ratio of 39.26, which suggests a moderately leveraged balance sheet rather than a conservative one, though the high current ratio of 4.10 demonstrates robust short-term liquidity to cover immediate obligations. Furthermore, the return on equity of 102.8% and return on assets of 9.4% highlight exceptional management effectiveness in generating returns relative to the shareholders' equity and the total asset base utilized.

估值评估

Valuation metrics show a trailing P/E ratio of 12.35 compared to a forward P/E of 13.89, a divergence that implies the market expects earnings growth to stabilize or increase slightly, resulting in a higher multiple on future projections than current performance warrants. The price-to-book ratio is recorded at 7.57, indicating that the market values the company's equity at a significant premium over its book value, reflecting the high intangible asset content typical of biotechnology firms. Alternative valuation measures include a price-to-sales ratio of 8.86 and an EV/EBITDA of 41.86, both of which suggest the market is willing to pay a high multiple for revenue and earnings, characteristic of growth-oriented biopharma assets. In terms of trading range, the stock has a 52-week high of $46.48 and a low of $25.28; without a specific current price provided in the facts, the absolute position relative to this range cannot be precisely calculated, but the range itself defines the volatility envelope for the security. Additionally, the beta value of 1.75 indicates that the stock's price volatility is substantially higher than the broader market, meaning it is expected to move 75% more than the market index during periods of fluctuation.

Growth & Income

Growth dynamics are characterized by a revenue growth rate of 78.0% year-over-year contrasted with an earnings growth rate of -6.1% year-over-year, implying that while top-line sales are expanding rapidly, net income is contracting, possibly due to increasing cost of goods sold, R&D expenses, or restructuring charges that are outpacing revenue gains. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, signifying that the firm retains all earnings to reinvest into its pipeline, clinical trials, and commercial expansion rather than distributing income to shareholders. This strategy aligns with the lifecycle of a commercial-stage biotech firm that prioritizes capital allocation toward growth opportunities over immediate shareholder returns. The overall growth and income profile thus presents a high-growth, zero-income trajectory where value creation is expected to stem from future product approvals and market share gains rather than current dividend payments.